Little information is available on the impact of direct-acting antiviral (DAA) therapy on changes in liver fibrosis and steatosis. Liver stiffness (LS) and controlled attenuation parameter (CAP) values were evaluated using transient elastography. The study subjects were 214 elderly patients infected with HCV genotype 1b who received 24-week daclatasvir and asunaprevir dual therapy. All patients of this retrospective study had no hepatocellular carcinoma before and during DAA therapy. LS and CAP were assessed before treatment (baseline), at end of treatment (EOT), and at 24, 48, 72 weeks (W) after EOT. The rate of sustained viral response (SVR) by daclatasvir and asunaprevir therapy was 91%. LS values for the entire group correlated with Fib-4 index at baseline (r = 0.565, P < 0.001). LS in both chronic hepatitis group (Fib-4 index <3.25) and cirrhosis group (Fib-4 index ≥3.25) decreased significantly at each time point compared with baseline (P < 0.001). Especially, a larger decrease in LS from baseline to EOT was seen in the cirrhosis group than chronic hepatitis group (P < 0.001). LS was also significantly lower in the SVR group at EOT, 24W, 48W, 72W compared with baseline (P < 0.001). Even in the non-SVR group, LS tended to be lower at EOT (P = 0.039), 24W (P = 0.009), 48W (P = 0.475), 72W (P = 0.033) compared with baseline. CAP increased significantly following the treatment from baseline to 48W post-EOT (P = 0.018). Our results showed significant improvement in LS in response to daclatasvir and asunaprevir dual therapy. In the other hand, there was a tendency that CAP increased from baseline.
in September 2014 by the Government National Health Insurance scheme for patients with chronic HCV-1b infection and has since its use shown promising results. 1, 2 However, there is little or no information on whether the DAA affects liver fibrosis or HCV-associated hepatocarcinogenesis.
Liver biopsy is still considered the gold standard for evaluation of liver fibrosis although it is an invasive procedure. 3 Based on this drawback of the procedure, especially making it unsuitable for repeated examinations, various non-invasive procedure have been recently reported for longitudinal evaluation of liver fibrosis. 4 One such method is the FIB-4 index, which is estimated using the values of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet count, and age. Previous studies showed that the FIB-4 index can be used to classify liver disease and monitor HCV-infected patients in longitudinal studies. 5, 6 Currently, measurement of liver stiffness (LS) by transient elastography (TE) with the use of FibroScan ® is widely used for the assessment of liver fibrosis. 7, 8 Previous studies demonstrated that the use of interferon helped reduce the risk of liver-related complications, such as hepatocellular carcinoma (HCC). 9, 10 With the recent enhancement in the FibroScan ® machine, including a new software, it is now possible to calculate the so called controlled attenuation parameter (CAP), which is a reliable noninvasive quantitative marker of hepatic steatosis, which is an independent factor associated with obesity. 11 Previous studies showed that hepatic steatosis is a risk factor for HCC in patients with chronic HCV infection.
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Based on the above background, the present study was designed to determine the effects of 24-week treatment with the combination of DCV and ASV on liver fibrosis and steatosis (assessed by LS and CAP).
| MATERIALS AND METHODS

| Study patients
Between September 2014 and June 2015, 24-week dual oral therapy of DCV and ASV was provided to 805 HCV genotype 1b patients at the Department of Hepatology, Toranomon Hospital.
The inclusion criteria used for enrolment and treatment were as follows: (1) positivity for HCV RNA genotype 1b and anti-HCV antibody, and no co-infection with other HCV genotypes; (2) absence of decompensated liver cirrhosis; and (3) lack of HCC requiring treatment. Cirrhosis was diagnosed with Fib-4 index ≥3.25, while chronic hepatitis C was diagnosed with Fib-4 index <3.25. In the present study, the Fib-4 index was used as a surrogate marker of liver fibrosis, as described previously. 5, 13 The primary endpoint of the study was a sustained virological response (SVR), that is, negative HCV-RNA at 12 weeks after the end of the 24-week dual therapy.
Among the 805 patients, 214 patients underwent both LS and CAP measurements with the TE at least twice during the follow-up period. These patients were selected as the subjects of this study. 
| Measurement of CAP
CAP was estimated at baseline, EOT, 24, 48, and 72 weeks post-EOT.
The CAP represents ultrasonic attenuation of the liver at 3. cirrhosis. There were no significant differences in LS and CAP at baseline between the SVR and non-SVR groups (LS; P = 0.772, CAP; P = 0.404). LS decreased significantly from baseline to EOT (P < 0.001), 24 (P < 0.001), 48 (P < 0.001), and 72 weeks post-EOT (P < 0.001). The difference in LS between each time point was as follows; EOT versus baseline (P < 0.001), 24 weeks versus EOT (P < 0.001), 48 versus 24 weeks (P = 0.298), 72 versus 48 weeks (P = 0.003). Moreover, the difference examined by multiple test was significant (P < 0.001). Figure 3B shows changes in LS in cirrhotic patients. LS decreased significantly from baseline to EOT (P < 0.001), 24 (P < 0.001), 48 (P < 0.001), and 72 weeks post-EOT (P < 0.001). The difference in LS between each time point was as follows; EOT versus baseline (P < 0.001), 24 versus EOT (P < 0.001), 48 versus 24 weeks (P = 0.094), 72 versus 48 weeks (P = 0.028). Especially, the decrease in LS from baseline to EOT in the cirrhotic group was larger than that in the chronic hepatitis group (P < 0.001). Furthermore, the difference examined by multiple test was significant (P < 0.001). Figure 4A shows changes in LS in the SVR group. LS decreased significantly from baseline to EOT (P < 0.001), 24 weeks (P < 0.001), 48 (P < 0.001), and 72 weeks post-EOT (P < 0.001). The difference examined by multiple test was significant (P < 0.001). Figure 5B Apart from the strengths of the present study described above, the study also has certain limitations. The present study is retrospective and a single center study. (3) The number of patients who could be followed-up decreased during the latter part of the study. While this is not uncommon in studies of this type of design, we believe there is a need to confirm the results in a prospective multicenter study that includes a large number of patients matched for race and HCV genotype to confirm the results reported in the present study. (4) Last, there is a need to examine the relation between hepatocarcinogenesis and the values of LS and CAP measured over a long period of time.
| Changes in Fib-4 index according to liver fibrosis
| Changes in LS according to treatment efficacy
In conclusion, we have demonstrated in the present study a decrease in LS following 24-week oral dual therapy with DAA regardless of the progression of liver fibrosis and response to the treatment. Especially, the decrease of LS, in cirrhosis, which is a high risk factor for hepatocarcinogenesis, was larger than in chronic hepatitis. These results suggest that DAA therapy for hepatitis C genotype 1b seems to suppress the risk of hepatocarcinogenesis. On other hand, the study showed a tendency for increase in CAP value following DAA therapy. Further studies are needed to evaluate the clinical significance of the change in CAP during the study.
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